All Videos

Shannon Trotter, DO, explores social media's impact on dermatology, lichenoid disorders, and granuloma annulare at SDPA Fall 2025.

Explore how a groundbreaking initiative by Hayden Middleton, PA-C, bridges dermatology and nutrition, enhancing patient care and clinician fulfillment.

Kassandra Holzem, MD, shares vital insights on dermatology red flags and GVHD management, enhancing oncology care at SDPA Fall 2025.

Kristine Kucera, PA-C, MPAS, DHS, reflects on her impactful 30-year career and celebrates the evolution of dermatology PAs at the SDPA Fall 2025 conference.

Explore the latest insights on psoriatic arthritis and psoriasis management from Shikha Singla, MD, emphasizing multidisciplinary care and early screening strategies.

SDPA Emerging Scholars share insights on mentorship and professional growth, highlighting the importance of collaboration in dermatology.

Panelists discuss how twice-daily dosing represents the biggest adherence challenge and how simplifying regimens from multiple location-specific medications to single versatile treatments significantly improves adherence, with once-daily formulations being much more manageable for busy families.

Panelists discuss how roflumilast demonstrated 25% Investigator’s Global Assessment (IGA) success at 4 weeks in the Integument PED trial with impressive long-term results showing 73% Eczema Area and Severity Index (EASI-75) achievement at 56 weeks, while highlighting its excellent tolerability profile with no black box warning, no folliculitis, and minimal stinging compared with previous phosphodiesterase-4 inhibitors.

Yasmine Kirkorian, MD, shares insights on pediatric dermatology advancements and genetic skin disorders at SDPA Fall 2025, emphasizing early diagnosis and innovative therapies.

Marc Serota, MD, discusses using ruxolitinib cream to safely maintain repigmentation, minimize steroid-related adverse effects, and enhance outcomes when combined with phototherapy.

Explore insights from SDPA leaders Renata Block, DMSc, MMS, PA-C, and Sarah Vicari, MMS, PA-C, on mentorship, volunteerism, and fostering growth for PAs.

Panelists discuss how the AHEAD recommendations establish structured, patient-centered treatment targets that help clinicians achieve measurable and lasting success in atopic dermatitis management.

Hilary Baldwin, MD, introduces the series and reviews acne pathogenesis, mechanisms of topical therapies, and key barriers to adherence in everyday practice.

A panelist discusses how the rise of convenient and accessible oral therapies is poised to redefine systemic treatment strategies, payer decisions, and clinical guidelines in dermatology.

Allergan Aesthetics pioneers regenerative skincare through secretome science, enhancing skin health with fibroblast-derived exosomes for transformative results.

Lindsay Ackerman, MD, explains the importance of transparency when prescribing medications with boxed warnings.

Discover how Prithwiraj Maitra, PhD, advances skin care innovation with exosomes, emphasizing scientific validation and ingredient transparency in cosmetic formulations.

New findings from LEO Pharma reveal chronic hand eczema affects 1 in 10 adults, highlighting the need for improved recognition and management in dermatology.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Panelists discuss how tapinarof showed strong efficacy in the Adoring trials, with 45% to 46% Investigator’s Global Assessment (IGA) success and 55% to 60% Eczema Area and Severity Index (EASI-75) achievement at 8 weeks. However, they question real-world adherence to daily application over such extended periods and note folliculitis as a notable adverse effect occurring in over 5% of patients.

Panelists discuss how ruxolitinib cream demonstrated impressive efficacy in the TRU83 trial, with over 50% of patients achieving near-complete clearance at 8 weeks using the 1.5% formulation, while acknowledging that the Janus kinase (JAK) inhibitor’s broad mechanism makes its effectiveness unsurprising despite concerns about the boxed warning.

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.

A panelist discusses how sustained efficacy, convenience, and safety of new oral therapies could transform pediatric psoriasis care and inform future clinical standards.

Chava Wald shares her inspiring journey with AD, advocating for patient empowerment and compassionate care during Eczema Awareness Month.

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

Panelists discuss how long-term management of melasma and postinflammatory hyperpigmentation requires lifelong maintenance regimens including retinoids for all patients, consistent sunscreen use with reapplication, proper diagnosis through biopsy when treatments fail to respond, and recognition that patients may have multiple concurrent conditions requiring different treatment approaches.

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

Panelists discuss how long-term use of JAK inhibitors provides durable, real-world efficacy and consistent disease control for patients with atopic dermatitis.

Lindsay Ackerman, MD, outlines how ruxolitinib topical has transformed the clinical approach to vitiligo.